Investor Presentaiton
R&D investor presentation
Data from a phase 2a trial with Ziltivekimab indicate lowering of
hsCRP, which is a marker for inflammation
Data from a phase 2a trial in CKD stage 5 patients
with inflammation
Trial design of ongoing phase 2b (RESCUE)
7.5 mg Q4W (66 patients)
15 mg Q4W (66 patients)
Placebo
Ziltivekimab
2 mg
6 mg
20 mg
N=61
12
16
16
17
% of patients
CKD stage 3-5
hsCRP >2
mg/L
30 mg Q4W (66 patients)
hsCRP<2.0
14.3
43.8
60.0
90.9*
mg/L, Week 12
Placebo Q4W (66 patients)
24-week treatment
Conclusions:
Ziltivekimab effectively reduces C-reactive protein (CRP)
in patients with CKD on dialysis
Ziltivekimab substantially reduced markers of
inflammation with a trend towards improving NT-proBNP
without adversely affecting lipoprotein lipids, neutrophils
or platelets
SOURCE: https://www.ahajournals.org/doi/10.1161/circ.140.suppl 1.13727.
Primary endpoint
Reduction of inflammation measured as reduction in C-
reactive protein
Purpose/timing
Determine a dose for a potential phase 3 CVOT
Phase 2 results expected H2 2020
hsCRP: High sensitivity C-reactive protein; CKD: chronic kidney disease; NT-proBNP: N-terminal-pro hormone BNP; Q4W: intravenously every 4 weeks; CVOT: cardiovascular outcomes trial
28View entire presentation